Tyrosylleucine TFA – Orally Active Antidepressant Dipeptide (GMP Grade)

描述

Tyrosylleucine TFA is a high-purity synthetic dipeptide combining the amino acids tyrosine and leucine (sequence Tyr-Leu), delivered as its trifluoroacetate (TFA) salt. This dipeptide demonstrates oral bioactivity and antidepressant-like effects in rodent models, making it a compelling candidate for research on emotional behavior, stress response, and neurogenesis.PubMed

Preclinical studies show Tyrosylleucine (often referred to as YL) reduces immobility in forced swim and tail suspension tests, behavioral paradigms used to gauge antidepressant effects, comparable to standard antidepressants like fluvoxamine and imipramine. It also promotes hippocampal progenitor cell proliferation, modulates stress hormone levels, and activates neural c-Fos expression—all through a mechanism independent of BDNF signaling.

Manufactured under GMP standards, our Tyrosylleucine TFA achieves 98.63% purity and is delivered as a lyophilized powder. Designed for reproducibility in laboratories, it supports both wholesale and retail scales. For laboratory research use only—no clinical or veterinary use intended.

Product Specifications

Derived from reputable sources like MedChemExpress and ChemicalBook, this dipeptide is validated as orally active and antidepressant-like in vivo.

Mechanism of Action & Research Applications

Tyrosylleucine TFA exerts antidepressant-like effects through multiple, well-documented mechanisms:

• Behavioral Efficacy: Demonstrated oral activity in rodent models—significant reductions in immobility in forced swim and tail suspension tests. Effectiveness comparable to mainstream antidepressants.

• Neurogenesis & c-Fos Activation: Increases hippocampal progenitor cell proliferation and expression of c-Fos, indicators of neuronal activation and neuroplasticity.

• Stress Axis Modulation: Suppresses stress-induced elevation of hypothalamic CRH and plasma corticosterone, demonstrating anxiolytic-stabilizing effects on the HPA axis.

• Receptor Signaling Pathway: Requires activation of serotonin 5-HT?A, dopamine D?, and GABA? receptors—despite no direct affinity to them—suggesting a downstream modulatory mechanism.

Research Applications include:

• Screening novel antidepressant-like molecules

• Investigating neurogenesis and stress resilience mechanisms

• Deciphering signal transduction in mood regulation

• Testing orally active dipeptide efficacy in translational models

  

Side Effects (For Reference in Models)

In preclinical settings, Tyrosylleucine TFA appears to lack off-target toxicity, with no observed negative effects on locomotion or behavior at effective doses. However, researchers are advised to account for:

• Dose-dependent effects—high doses may induce receptor adaptations

• Potential satiety or metabolic modulation—due to peptide nature

• Species-specific responses—rodent data may not translate directly

These are general considerations and not clinical warnings.

Disclaimer

Tyrosylleucine TFA is provided strictly for laboratory research use only. It is not intended for human consumption, clinical treatment, diagnostics, or veterinary use. Compliance with institutional safety and handling guidelines is mandatory.

Keywords

Tyrosylleucine TFA, Tyr-Leu dipeptide, antidepressant dipeptide, orally active peptide, hippocampal progenitor proliferation, GMP peptide supplier, antidepressant research dipeptide, neurogenesis peptide, stress response modulation, research-grade TyrLeu peptide